A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/05/2002	US6475795 Use of hyaluronan in gene therapy
11/05/2002	US6475746 Method of obtaining a composition comprising a 5-HT1D selective compound
11/05/2002	US6475724 Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
11/05/2002	US6475718 Genetically engineered eukaryotic cell; for prevention of viral infections; viricides
11/05/2002	US6475530 Methods and compositions for producing weight loss
11/05/2002	US6475524 Composition of matter
11/05/2002	US6475518 Methods and compositions for treatment of disorders associated with chlamydia and similar bacterial infection
11/05/2002	US6475514 Athletic patch
11/05/2002	US6475508 Methods and pharmaceutical compositions for the closure of retinal breaks
11/05/2002	US6475506 Infusion preparation
11/05/2002	US6475494 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency
11/05/2002	US6475491 Treatment of HIV and other viral infections using combinatorial therapy
11/05/2002	US6475371 Method and apparatus for producing electrolytic reduced water
11/05/2002	CA2252670C Low ph acidic compositions
11/04/2002	WO2004001058A2 Transcription factor modulating compounds and methods of use thereof
11/01/2002	CA2384227A1 Combination treatment for anxiety and depression
10/2002
10/31/2002	WO2002086443A2 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002	WO2002086161A1 Method of estimating diplotype from genotype of individual
10/31/2002	WO2002086113A2 Enzyme and snp marker for disease
10/31/2002	WO2002086090A2 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002	WO2002086079A2 T1r3 a novel taste receptor
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085943A2 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085886A2 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002	WO2002085459A2 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002	WO2002085458A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/31/2002	WO2002085446A2 Microprojection array immunization patch and method
10/31/2002	WO2002085414A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
10/31/2002	WO2002085405A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
10/31/2002	WO2002085402A1 Methods and compositions for treating oral and eosophageal lesions
10/31/2002	WO2002085400A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
10/31/2002	WO2002085382A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002	WO2002085381A1 Method for treating gout and binding uric acid
10/31/2002	WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	WO2002085365A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002	WO2002085364A1 Farnesyl protein transferase inhibitors for treating cachexia
10/31/2002	WO2002085359A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases
10/31/2002	WO2002085351A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002	WO2002085349A1 Use of active substance combinations from alpha lipoic acid and substances that absorb light in the uv-a and/or uv-b range for use in the treatment and/or prophylaxis of undesired cutaneous pigmentation
10/31/2002	WO2002085342A2 Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
10/31/2002	WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002	WO2002085327A2 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
10/31/2002	WO2002085309A2 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
10/31/2002	WO2002085308A2 Antisense and anti-inflammatory based compositions to treat respiratory disorders
10/31/2002	WO2002085304A2 Proliposomal drug delivery system
10/31/2002	WO2002085301A2 Indole, azaindole and related heterocyclic amidopiperazine derivatives
10/31/2002	WO2002085296A2 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
10/31/2002	WO2002085248A2 Prostanoids augment ocular drug penetration
10/31/2002	WO2002085124A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002	WO2002085123A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002	WO2002070737A8 Compositions and methods relating to osteoarthritis
10/31/2002	WO2002067853A3 A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
10/31/2002	WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002	WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002	WO2002053564A3 Quinuclidine derivatives and their use as m3 antagonists
10/31/2002	WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002	WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002	WO2002042455A3 Modifier of organelle metalbolism
10/31/2002	WO2002036105A3 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
10/31/2002	WO2002034913A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/31/2002	WO2002026217A3 Composition for the transdermal delivery of fentanyl
10/31/2002	WO2002024912A3 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
10/31/2002	WO2002014499A3 Claudin polypeptides
10/31/2002	WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002	WO2001056563A9 Adamantyl derivatives as anti-cancer agents
10/31/2002	WO2001055432A3 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
10/31/2002	US20020162129 Prevention and treatment of alzheimer's disease
10/31/2002	US20020161048 Glycine substitutes and precursors for treating a psychosis
10/31/2002	US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002	US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002	US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake
10/31/2002	US20020161026 Combination therapies for the stimulation of bone growth
10/31/2002	US20020161020 Stablization of quinapril using magnesium oxide
10/31/2002	US20020161017 For amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to mammal
10/31/2002	US20020161016 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
10/31/2002	US20020161009 Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
10/31/2002	US20020160993 Method for treating glaucoma IC
10/31/2002	US20020160981 For treatment or prophylaxis of thromboembolic diseases in a mammal having had transluminal angioplasty, synthetic oligosaccharide selective inhibitor of factor Xa acting via antithrombin III and aspirin
10/31/2002	US20020160980 Method of treating hepatitis delta virus infection
10/31/2002	US20020160978 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
10/31/2002	US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002	US20020160973 Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
10/31/2002	US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002	US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002	US20020160955 Protein variants
10/31/2002	US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002	US20020160933 Methods and compositions for producing a neurosalutary effect in a subject
10/31/2002	US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002	US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002	US20020160477 CAF1-related protein
10/31/2002	US20020160447 Ups (ugc)
10/31/2002	US20020160438 Modulate kinase; antiinflammatory agents; respiratory system disorders
10/31/2002	US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002	US20020160362 Measurement variations of allele polypeptides gene; diagnosis of arthritis, cancer
10/31/2002	US20020160052 Tissue graft composition comprising liver basement membrane; graft composition can be implanted to replace or induce repair of damaged or diseased tissues
10/31/2002	US20020160040 Cubic liquid crystalline compositions and methods for their preparation
10/31/2002	US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002	US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002	US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders

1 ... 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 ... 1151